Details of Disease

General Information of Disease (ID: DISOR9PQ)

• Disease Name: Spinal cord injury
• Synonyms: spinal cord Contusions; cord Contusions, spinal; spinal cord Transections; cord trauma, spinal; post traumatic myelopathy; myelopathy, post-traumatic; laceration, spinal cord; myelopathy, traumatic; cord injury, spinal; post-traumatic myelopathy; spinal cord laceration; cord contusion, spinal; Contusions, spinal cord; post-traumatic Myelopathies; Myelopathies, post-traumatic; spinal cord Lacerations; Traumas, spinal cord; Lacerations, spinal cord; injury, spinal cord; spinal cord transection; traumatic myelopathy; spinal cord trauma; Myelopathies, traumatic; trauma, spinal cord; cord Transections, spinal; cord laceration, spinal; traumatic Myelopathies; cord transection, spinal; cord Traumas, spinal; contusion, spinal cord; Injuries, spinal cord; cord Lacerations, spinal; spinal cord contusion; transection, spinal cord; spinal cord Traumas; cord Injuries, spinal; Transections, spinal cord; injury of spinal cord; spinal cord injury
• Disease Class: ND51: Spine/trunk injury
• Definition: Penetrating and non-penetrating injuries to the spinal cord resulting from traumatic external forces (e.g., WOUNDS, GUNSHOT; WHIPLASH INJURIES; etc.).
• Disease Hierarchy:
  DISXV8FG: Myelopathy
  DISKB4RK: Injury
  DISQRITY: Spinal disease
  DIS1DVJH: Nervous system injury
  DISO0NRV: Spinal injury
  DISOR9PQ: Spinal cord injury
• ICD Code: ICD-11: ICD-11: ND51.2

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 2 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Iophendylate	DMI0GUM	Approved	Small molecular drug	[1]
Methylprednisolone	DM4BDON	Approved	Small molecular drug	[2]

This Disease is Treated as An Indication in 16 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Autologous stem cell therapy	DMGQPP8	Phase 3	NA	[3]
MultiStem	DMOT705	Phase 3	NA	[4]
VX-210	DM5G1NT	Phase 2/3	NA	[5]
AC-105	DMW8BY2	Phase 2	NA	[6]
CX-717	DMM65W1	Phase 2	Small molecular drug	[7]
Elezanumab	DMCSXI4	Phase 2	Antibody	[8]
NSI-566	DMHHXC9	Phase 2	NA	[7]
ProCord	DMSTSWI	Phase 2	NA	[9]
Tempol	DMUQH78	Phase 2	Small molecular drug	[10]
Tissue Repair Cells (TRCs)	DMKC26W	Phase 2	NA	[11]
AST-OPC1	DMUKG47	Phase 1/2	NA	[7]
Cethrin	DMD3XMW	Phase 1/2	Small molecular drug	[12]
hESC-derived oligodendrocyte progenitors (AST-OPC1)	DMBP4YP	Phase 1/2	Human embryonic stem (hES) cell-derived therapeutics	[13]
ALMB-0166	DM3MH2H	Phase 1	NA	[14]
GRNOPC-1	DMYK3MS	Phase 1	NA	[15]
Privigen	DMWF3C6	Phase 1	NA	[7]

This Disease is Treated as An Indication in 7 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AM-250	DM76HLL	Investigative	NA	[16]
NGN-9080	DMKDKQ9	Investigative	NA	[16]
NX-210	DM02FCI	Investigative	NA	[16]
ODN-2088	DM692XV	Investigative	Oligonucleotide	[17]
PR-21	DMVZO9D	Investigative	NA	[16]
Stem cell therapy, spinal cord injury	DMDJ44W	Investigative	NA	[16]
STP-805	DMZLMLR	Investigative	NA	[16]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7088).
• [3] Fifteen Cell Therapies/Stem Cell Therapies in Phase III Clinical Trials.
• [4] ClinicalTrials.gov (NCT02277613) A Phase 2 Trial of AMI MultiStem Therapy in Subjects With Non-ST Elevation Acute Myocardial Infarction. U.S. National Institutes of Health.
• [5] ClinicalTrials.gov (NCT02669849) Study to Assess the Efficacy and Safety of VX-210 in Subjects With Acute Traumatic Cervical Spinal Cord Injury. U.S. National Institutes of Health.
• [6] ClinicalTrials.gov (NCT01750684) A Study of AC105 in Patients With Acute Traumatic Spinal Cord Injury. U.S. National Institutes of Health.
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] ClinicalTrials.gov (NCT04295538) Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI) (ELASCI). U.S. National Institutes of Health.
• [9] Clinical pipeline report, company report or official report of Proneuron Biotechnologies.
• [10] ClinicalTrials.gov (NCT00801086) Efficacy Study of Tempol to Prevent Hair Loss From Radiotherapy to the Brain. U.S. National Institutes of Health.
• [11] Aastrom Biosciences Receives NIH Grant Extending Proprietary Adult Stem Cell Process to Other Tissues
• [12] Emerging drugs for spinal cord injury. Expert Opin Emerg Drugs. 2008 Mar;13(1):63-80.
• [13] ClinicalTrials.gov (NCT02302157) Dose Escalation Study of AST-OPC1 in Spinal Cord Injury
• [14] ClinicalTrials.gov (NCT05524103) A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ALMB-0166 in Patients With Acute Spinal Cord Injury. U.S.National Institutes of Health.
• [15] Clinical pipeline report, company report or official report of Geron Corp.
• [16] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [17] Toll-like receptor 9 antagonism modulates astrocyte function and preserves proximal axons following spinal cord injury. Brain Behav Immun. 2019 Aug;80:328-343.